Epstein-Barr virus associated lymphoproliferative disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Epstein-Barr virus associated lymphoproliferative disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure https://clinicaltrials.eu/trial/study-of-tabelecleucel-for-patients-with-epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-after-transplant-treatment-failure/ Wed, 29 Apr 2026 14:58:57 +0000 https://clinicaltrials.eu/trial/study-of-tabelecleucel-for-patients-with-epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-after-transplant-treatment-failure/ This clinical trial is focused on studying a condition known as Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD). This disease can occur in patients who have undergone organ or cell transplants and is associated with the Epstein-Barr virus. The study is investigating a treatment called tabelecleucel, also known by its code name ATA129. Tabelecleucel is a type of cell therapy that uses specially prepared cells to target and fight the virus-related disease.

The purpose of the study is to determine the clinical benefit of tabelecleucel in patients with EBV+ PTLD who have not responded to previous treatments, such as rituximab or rituximab combined with chemotherapy. Participants in the study will receive tabelecleucel through an injection into their veins. The study will monitor how well the treatment works and how the disease responds over time.

Participants will be observed throughout the study to assess the effects of the treatment. The study aims to provide valuable information on the effectiveness of tabelecleucel for patients with EBV+ PTLD, offering insights into potential new treatment options for those who have not had success with existing therapies. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the treatment’s impact.

]]> Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases https://clinicaltrials.eu/trial/study-on-tabelecleucel-for-patients-with-epstein-barr-virus-associated-diseases/ Wed, 29 Apr 2026 14:58:44 +0000 https://clinicaltrials.eu/trial/study-on-tabelecleucel-for-patients-with-epstein-barr-virus-associated-diseases/ This clinical trial is focused on studying diseases associated with the Epstein-Barr Virus (EBV). These diseases include EBV-associated post-transplant lymphoproliferative disorder (PTLD), which can affect the central nervous system, EBV-associated primary immunodeficiency lymphoproliferative disease (LPD), and EBV-associated sarcomas, such as leiomyosarcoma or smooth muscle tumors. The trial also includes cases where standard treatments like rituximab or chemotherapy are not suitable. The treatment being tested is called tabelecleucel, also known by its code name ATA129. Tabelecleucel is a type of cell therapy that uses specially prepared cells to target and fight the virus-related diseases.

The purpose of this study is to evaluate the benefits of using tabelecleucel in patients with these EBV-associated diseases. Participants in the study will receive tabelecleucel through an injection into a vein. The study will monitor how well the treatment works and its safety over a period of time. The study is designed to see how many patients respond to the treatment and how long the response lasts. It will also look at overall survival rates and how long patients live without the disease getting worse.

The study will follow participants to gather information on the effectiveness of tabelecleucel in treating these conditions. The goal is to determine if this treatment can provide a clinical benefit to patients with EBV-associated diseases. The study will continue until the estimated end date in 2026, with the aim of collecting comprehensive data on the treatment’s impact on these serious conditions.

]]>